APA (7th ed.) Citation

M, Z., R, A., S, F. A., S, K., N, E., A, A., . . . B, Y. (2024). Safety and effectiveness of disease-modifying therapies after switching from natalizumab. Multiple sclerosis (Houndmills, Basingstoke, England), 30(8), 1026. https://doi.org/10.1177/13524585241261565

Chicago Style (17th ed.) Citation

M, Zeineddine, et al. "Safety and Effectiveness of Disease-modifying Therapies After Switching from Natalizumab." Multiple Sclerosis (Houndmills, Basingstoke, England) 30, no. 8 (2024): 1026. https://doi.org/10.1177/13524585241261565.

MLA (9th ed.) Citation

M, Zeineddine, et al. "Safety and Effectiveness of Disease-modifying Therapies After Switching from Natalizumab." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 30, no. 8, 2024, p. 1026, https://doi.org/10.1177/13524585241261565.